Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Myocardial Ischemia - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Myocardial Ischemia - Pipeline Review, H2 2016', provides an overview of the Myocardial Ischemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia - The report reviews pipeline therapeutics for Myocardial Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Myocardial Ischemia therapeutics and enlists all their major and minor projects - The report assesses Myocardial Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Myocardial Ischemia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Myocardial Ischemia Overview 8 Therapeutics Development 9 Pipeline Products for Myocardial Ischemia - Overview 9 Pipeline Products for Myocardial Ischemia - Comparative Analysis 10 Myocardial Ischemia - Therapeutics under Development by Companies 11 Myocardial Ischemia - Therapeutics under Investigation by Universities/Institutes 12 Myocardial Ischemia - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Myocardial Ischemia - Products under Development by Companies 16 Myocardial Ischemia - Products under Investigation by Universities/Institutes 17 Myocardial Ischemia - Companies Involved in Therapeutics Development 18 Bayer AG 18 Cellmid Limited 19 CohBar, Inc. 20 Lixte Biotechnology Holdings, Inc. 21 Miltenyi Biotec GmbH 22 NoNO, Inc. 23 Shire Plc 24 Symic Biomedical, Inc. 25 Taxus Cardium Pharmaceuticals Group Inc. 26 ViroMed Co., Ltd. 27 Myocardial Ischemia - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 AB-002 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Alda-1 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 alferminogene tadenovec - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 AntimiR-199a - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 BAY-606583 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 CMK-103 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 EP-80317 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Humanin - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 LB-100 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Peptagon - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 PMC-6 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 SB-030 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Stem Cell Therapy for Cardiovascular Disease - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 VM-202 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Myocardial Ischemia - Dormant Projects 68 Myocardial Ischemia - Discontinued Products 69 Myocardial Ischemia - Product Development Milestones 70 Featured News & Press Releases 70 May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities 70 Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 71 Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City 72 Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology 72 Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention 73 Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings 73 May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 74 Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 76 Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy 78 Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study 78 Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition 79 Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease 80 Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 82 Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA 82 Appendix 83 Methodology 83 Coverage 83 Secondary Research 83 Primary Research 83 Expert Panel Validation 83 Contact Us 83 Disclaimer 84
List of Tables
Number of Products under Development for Myocardial Ischemia, H2 2016 9 Number of Products under Development for Myocardial Ischemia - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Myocardial Ischemia - Pipeline by Bayer AG, H2 2016 18 Myocardial Ischemia - Pipeline by Cellmid Limited, H2 2016 19 Myocardial Ischemia - Pipeline by CohBar, Inc., H2 2016 20 Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 21 Myocardial Ischemia - Pipeline by Miltenyi Biotec GmbH, H2 2016 22 Myocardial Ischemia - Pipeline by NoNO, Inc., H2 2016 23 Myocardial Ischemia - Pipeline by Shire Plc, H2 2016 24 Myocardial Ischemia - Pipeline by Symic Biomedical, Inc., H2 2016 25 Myocardial Ischemia - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2016 26 Myocardial Ischemia - Pipeline by ViroMed Co., Ltd., H2 2016 27 Assessment by Monotherapy Products, H2 2016 28 Number of Products by Stage and Target, H2 2016 30 Number of Products by Stage and Mechanism of Action, H2 2016 32 Number of Products by Stage and Route of Administration, H2 2016 34 Number of Products by Stage and Molecule Type, H2 2016 36 Myocardial Ischemia - Dormant Projects, H2 2016 68 Myocardial Ischemia - Discontinued Products, H2 2016 69
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
